Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
ANNE GOLDFELD · BOSTON CHILDREN'S HOSPITAL · 2021 · $209,375 — Ebola virus (EBOV) and Marburg virus (MARV) are highly lethal hemorrhagic fever viruses of the Filoviridae family of viruses. Currently, there are no effective oral or easily scalable therapies for either virus. Both EBOV and MARV manifest vigorous anti-host evasion strategies focused on blocking th…
Edward N Janoff · VA EASTERN COLORADO HEALTH CARE SYSTEM · 2021 — 7. Project Summary/Abstract Both advancing age and HIV-1 infection are associated with an increased frequency of infection, such as those due to Streptococcus pneumoniae, and a higher rate of complications and death with these infections. Vaccines are available to prevent a number of infections comm…
YOSHIHIRO KAWAOKA · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $194,271 — PROJECT SUMMARY Ebola viruses and other members of the filovirus family cause severe and often lethal infections. While some progress has been made in regards to the development of experimental countermeasures and insights into the highly pathogenic nature of these viruses, there are still many more…
Kari Ann Shirey · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $231,750 — SUMMARY Influenza is a highly contagious respiratory illness that the CDC has estimated to afflict ~47.5 million Americans with up to 62,00 deaths from October 1, 2019 to April 4, 2020. In the absence of a “universal influenza vaccine,” yearly vaccination is strongly recommended; however, the compo…
Michael Daniel Keller · CHILDREN'S RESEARCH INSTITUTE · 2021 · $89,250 — Abstract Chronic norovirus infection can cause chronic diarrhea and wasting in immunocompromised patients, including those undergoing hematopoietic stem cell transplantation and with primary immunodeficiency disorders. There are currently no available therapies to treat norovirus. Our preliminary da…
EVAN J ANDERSON · EMORY UNIVERSITY · 2021 · $655,337 — Summary/Abstract The Emory VTEU has proven essential in the fight against the pandemic. This supplement will allow for further investigations into vaccines trials (21-0002). 1…
Angela Ramona Branche · UNIVERSITY OF ROCHESTER · 2021 · $1,144,400 — The Vaccine and Treatment Evaluation Units (VTEUs) are a critical resource for the NIAID Infectious Diseases Clinical Research Consortium to conduct clinical research and trials to evaluate vaccines, preventive biologics, therapeutics, diagnostics, predictive markers, and devices for the treatment a…
Wen Jiang · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2021 · $253,377 — Project Summary Despite significant advances in the treatment of breast cancer, the metastatic form of the disease remains highly lethal, with a 5-year overall survival rate of only around 20%. Even with the use of new, targeted therapies such as antibodies against the human epidermal receptor 2 (H…
Nathan G. Salomonis · CINCINNATI CHILDRENS HOSP MED CTR · 2021 · $238,489 — PROJECT SUMMARY: Alternative splicing is among the most important contributors of proteomic diversity in higher order eukaryotes. When disrupted in cancer, mis-splicing results in unique mRNA isoforms not observed in healthy cells. Such cancer-specific splice isoforms represent an untapped reservoir…
Joel H Collier · DUKE UNIVERSITY · 2021 · $435,384 — Even when vaccines are rapidly developed and shown to be efficacious and safe, vaccination campaigns continue to be hampered by public hesitancy and by challenges distributing vaccines equitably around the globe. Vaccine hesitancy, where individuals refuse or delay vaccination, has been a persistent…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2021 · $250,000 — Project Summary The goal of this Center of Biomedical Research Excellence is to continue our efforts to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approa…
VICTOR Robert DEFILIPPIS · OREGON HEALTH & SCIENCE UNIVERSITY · 2021 · $768,168 — PROJECT SUMMARY The goals of this R01 proposal include the molecular and immunological characterization of vaccine adjuvant activity associated with processes mediated by the protein Stimulator of Interferon Genes (STING). Two vital insufficiencies are currently evident regarding adjuvanted human va…
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $1,397,532 — ABSTRACT – Overall Nearly 600,000 new HIV infections occur yearly in adolescents/young adults (ages 15-24 years), the only population in which HIV infections continue to rise. The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can elicit long-term protective i…
Susan Moir · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $82,447 — In 2021, we contributed to several clinical research studies on COVID-19. We evaluated B cells following infection and/or vaccination, as well as innate cells in patients hospitalized with COVID-19. Our efforts were focused on three general study groups: 1) individuals hospitalized at the NIH clinic…
Lothar Hennighausen · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $3,036,975 — Objective 1 SARS-CoV-2 infection ranges from asymptomatic to severe with lingering symptomatology in some. We have conducted three clinical studies addressing newly emerging questions and problems as the pandemic progressed. Although a large percentage of infected individuals are asymptomatic, the r…
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $2 — The overall goals of the Animal Models Core is to support all programs of the IPCAVD by performing immunization studies in DH270 unmutated common ancestor (UCA) VH + VL knock-in (KI) mice with V3- Man9 glycopeptide primes and modified mRNA boosts (Project 1, Aim 2), by performing immunization studie…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $1,123,296 — We previously performed codon-pair deoptimization (CPD) of various open reading frames (ORFs) of RSV. This is done by rearranging codons of RSV open reading frames using computer algorithms and de novo gene synthesis to increase the content of normally underrepresented codon-pairs without changing a…
David Sacks · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $626,795 — Tissue-resident macrophages (TRMs) maintain tissue homeostasis, but they can also provide a replicative niche for intracellular pathogens such as Leishmania. We have identified a population of M2-like dermal macrophages that are present under steady state conditions and that are preferentially infec…
BRIAN KELSALL · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $2,029,000 — This project focuses on the roles of different populations of dendritic cells (DC) and macrophages (MP) in immune responses in mucosal tissues. While it is clear that the normal outcome of mucosal antigen exposure can be positive, i.e., the development of intestinal IgA and effector T cell responses…
Masaru Kanekiyo · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $22,147,857 — Improvements in vaccines against influenza that increase potency, breadth and durability of protection would improve worldwide ability to combat seasonal changes in influenza viruses (drift) and emergence of new pandemic strains (shift). This study aims to develop new platforms and vaccination strat…